vs

Side-by-side financial comparison of CHART INDUSTRIES INC (GTLS) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.

CHART INDUSTRIES INC is the larger business by last-quarter revenue ($1.1B vs $699.9M, roughly 1.5× QuidelOrtho Corp). CHART INDUSTRIES INC runs the higher net margin — 5.0% vs -104.7%, a 109.7% gap on every dollar of revenue. On growth, CHART INDUSTRIES INC posted the faster year-over-year revenue change (-2.5% vs -3.7%). CHART INDUSTRIES INC produced more free cash flow last quarter ($66.2M vs $-94.7M). Over the past eight quarters, CHART INDUSTRIES INC's revenue compounded faster (6.6% CAGR vs -2.9%).

Oricon Inc. , established in 1999, is the holding company at the head of a Japanese corporate group that supplies statistics and information on music and the music industry in Japan and Western music. It started as Original Confidence Inc. , which was founded by Sōkō Koike in November 1967 and became known for its music charts. Oricon Inc. was originally set up as a subsidiary of Original Confidence and took over the latter's Oricon record charts in April 2002.

QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.

GTLS vs QDEL — Head-to-Head

Bigger by revenue
GTLS
GTLS
1.5× larger
GTLS
$1.1B
$699.9M
QDEL
Growing faster (revenue YoY)
GTLS
GTLS
+1.3% gap
GTLS
-2.5%
-3.7%
QDEL
Higher net margin
GTLS
GTLS
109.7% more per $
GTLS
5.0%
-104.7%
QDEL
More free cash flow
GTLS
GTLS
$160.9M more FCF
GTLS
$66.2M
$-94.7M
QDEL
Faster 2-yr revenue CAGR
GTLS
GTLS
Annualised
GTLS
6.6%
-2.9%
QDEL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
GTLS
GTLS
QDEL
QDEL
Revenue
$1.1B
$699.9M
Net Profit
$53.6M
$-733.0M
Gross Margin
33.3%
Operating Margin
11.6%
-100.7%
Net Margin
5.0%
-104.7%
Revenue YoY
-2.5%
-3.7%
Net Profit YoY
-32.7%
-3583.4%
EPS (diluted)
$1.06
$-10.78

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GTLS
GTLS
QDEL
QDEL
Q4 25
$1.1B
Q3 25
$1.1B
$699.9M
Q2 25
$1.1B
$613.9M
Q1 25
$1.0B
$692.8M
Q4 24
$1.1B
$707.8M
Q3 24
$1.1B
$727.1M
Q2 24
$1.0B
$637.0M
Q1 24
$950.7M
$711.0M
Net Profit
GTLS
GTLS
QDEL
QDEL
Q4 25
$53.6M
Q3 25
$-138.5M
$-733.0M
Q2 25
$76.1M
$-255.4M
Q1 25
$49.5M
$-12.7M
Q4 24
$79.6M
$-178.4M
Q3 24
$69.0M
$-19.9M
Q2 24
$58.6M
$-147.7M
Q1 24
$11.3M
$-1.7B
Gross Margin
GTLS
GTLS
QDEL
QDEL
Q4 25
33.3%
Q3 25
34.1%
Q2 25
33.6%
Q1 25
33.9%
Q4 24
33.6%
Q3 24
34.1%
Q2 24
33.8%
Q1 24
31.8%
Operating Margin
GTLS
GTLS
QDEL
QDEL
Q4 25
11.6%
Q3 25
-8.0%
-100.7%
Q2 25
15.7%
-29.4%
Q1 25
15.2%
4.7%
Q4 24
17.0%
-14.2%
Q3 24
16.8%
2.1%
Q2 24
16.1%
-18.4%
Q1 24
11.9%
-247.3%
Net Margin
GTLS
GTLS
QDEL
QDEL
Q4 25
5.0%
Q3 25
-12.6%
-104.7%
Q2 25
7.0%
-41.6%
Q1 25
4.9%
-1.8%
Q4 24
7.2%
-25.2%
Q3 24
6.5%
-2.7%
Q2 24
5.6%
-23.2%
Q1 24
1.2%
-239.9%
EPS (diluted)
GTLS
GTLS
QDEL
QDEL
Q4 25
$1.06
Q3 25
$-3.23
$-10.78
Q2 25
$1.53
$-3.77
Q1 25
$0.94
$-0.19
Q4 24
$1.57
$-2.54
Q3 24
$1.33
$-0.30
Q2 24
$1.10
$-2.20
Q1 24
$0.10
$-25.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GTLS
GTLS
QDEL
QDEL
Cash + ST InvestmentsLiquidity on hand
$366.0M
$98.1M
Total DebtLower is stronger
$3.7B
$2.5B
Stockholders' EquityBook value
$3.2B
$2.0B
Total Assets
$9.8B
$5.7B
Debt / EquityLower = less leverage
1.13×
1.23×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GTLS
GTLS
QDEL
QDEL
Q4 25
$366.0M
Q3 25
$399.2M
$98.1M
Q2 25
$342.3M
$151.7M
Q1 25
$296.2M
$127.1M
Q4 24
$308.6M
$98.3M
Q3 24
$310.2M
$143.7M
Q2 24
$247.4M
$107.0M
Q1 24
$191.9M
$78.5M
Total Debt
GTLS
GTLS
QDEL
QDEL
Q4 25
$3.7B
Q3 25
$2.5B
Q2 25
$2.1B
Q1 25
$2.1B
Q4 24
$3.8B
$2.1B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$2.2B
Stockholders' Equity
GTLS
GTLS
QDEL
QDEL
Q4 25
$3.2B
Q3 25
$3.2B
$2.0B
Q2 25
$3.4B
$2.8B
Q1 25
$3.0B
$3.0B
Q4 24
$2.8B
$3.0B
Q3 24
$3.0B
$3.2B
Q2 24
$2.7B
$3.2B
Q1 24
$2.7B
$3.3B
Total Assets
GTLS
GTLS
QDEL
QDEL
Q4 25
$9.8B
Q3 25
$9.8B
$5.7B
Q2 25
$9.7B
$6.4B
Q1 25
$9.3B
$6.5B
Q4 24
$9.1B
$6.4B
Q3 24
$9.5B
$6.8B
Q2 24
$9.3B
$6.7B
Q1 24
$9.2B
$6.7B
Debt / Equity
GTLS
GTLS
QDEL
QDEL
Q4 25
1.13×
Q3 25
1.23×
Q2 25
0.74×
Q1 25
0.70×
Q4 24
1.33×
0.72×
Q3 24
0.68×
Q2 24
0.70×
Q1 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GTLS
GTLS
QDEL
QDEL
Operating Cash FlowLast quarter
$88.8M
$-45.5M
Free Cash FlowOCF − Capex
$66.2M
$-94.7M
FCF MarginFCF / Revenue
6.1%
-13.5%
Capex IntensityCapex / Revenue
2.1%
7.0%
Cash ConversionOCF / Net Profit
1.66×
TTM Free Cash FlowTrailing 4 quarters
$202.8M
$-153.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GTLS
GTLS
QDEL
QDEL
Q4 25
$88.8M
Q3 25
$118.0M
$-45.5M
Q2 25
$145.9M
$-46.8M
Q1 25
$-60.0M
$65.6M
Q4 24
$281.4M
$63.7M
Q3 24
$200.6M
$117.9M
Q2 24
$116.1M
$-97.9M
Q1 24
$-95.1M
$-700.0K
Free Cash Flow
GTLS
GTLS
QDEL
QDEL
Q4 25
$66.2M
Q3 25
$94.7M
$-94.7M
Q2 25
$122.0M
$-84.3M
Q1 25
$-80.1M
$9.4M
Q4 24
$260.9M
$16.5M
Q3 24
$174.5M
$71.4M
Q2 24
$88.0M
$-133.2M
Q1 24
$-141.2M
$-66.8M
FCF Margin
GTLS
GTLS
QDEL
QDEL
Q4 25
6.1%
Q3 25
8.6%
-13.5%
Q2 25
11.3%
-13.7%
Q1 25
-8.0%
1.4%
Q4 24
23.6%
2.3%
Q3 24
16.4%
9.8%
Q2 24
8.5%
-20.9%
Q1 24
-14.9%
-9.4%
Capex Intensity
GTLS
GTLS
QDEL
QDEL
Q4 25
2.1%
Q3 25
2.1%
7.0%
Q2 25
2.2%
6.1%
Q1 25
2.0%
8.1%
Q4 24
1.9%
6.7%
Q3 24
2.5%
6.4%
Q2 24
2.7%
5.5%
Q1 24
4.8%
9.3%
Cash Conversion
GTLS
GTLS
QDEL
QDEL
Q4 25
1.66×
Q3 25
Q2 25
1.92×
Q1 25
-1.21×
Q4 24
3.54×
Q3 24
2.91×
Q2 24
1.98×
Q1 24
-8.42×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GTLS
GTLS

Repair Service And Leasing Segment$330.4M31%
Heat Transfer Systems Segment$325.8M30%
Specialty Products Segment$259.5M24%
Transferred Over Time$94.4M9%
Transferred At Point In Time$69.5M6%

QDEL
QDEL

Labs$373.8M53%
Point Of Care$164.6M24%
Immunohematology$142.0M20%
Donor Screening$14.7M2%
Molecular Diagnostics$4.8M1%
Collaborative Arrangement Transaction With Party To Collaborative Arrangement$2.1M0%

Related Comparisons